DOCSLIB.ORG

DWS Aktien Schweiz

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
DWS Aktien Schweiz Marketing Material DWS Aktien Schweiz Equity Funds - Europe - Regions/Countries August 2021 As at 31/08/2021 Fund Data Performance Investment Policy Performance - Share Class CHF LC (in %) The fund's assets are predominantly invested in Swiss blue chips with an international reputation. Alongside the fund invests in selected small and mid caps with sound growth perspectives in our opinion. Fund Benchmark: SPI (RI) Past performance is no indication of current or future performance, and the performance data do not take account of the commissions and costs Fund Management's Comment incurred on the issue and redemption of units. In August, the SPI gained 2.59% to close at 15,947.7. August has often been a weak equity market month in the past. That was not the case this year, however. Investors Cumulative performance (in %) - share class CHF LC enjoyed the strong profit performance of 1 m 1 y 3 y 5 y s. Inception YTD 3 y avg 5 y avg 2017 2018 2019 2020 companies (Alcon); in addition investment alternatives still appear unattractive. The deteriorating coronavirus situation put a CHF 3.3 32.6 48.4 -0.1 -0.1 24.2 14.1 0.0 20.8 -11.8 29.0 5.8 damper on the good mood at times EUR 3.0 31.9 55.1 -0.1 -0.1 24.8 15.7 0.0 11.1 3.2 33.4 6.2 (Richemont and Swatch). Investors continue to focus on stocks with good growth BM IN CHF 2.4 26.0 48.5 78.9 122.3 19.7 14.1 12.3 19.9 -8.6 30.6 3.8 prospects such as Straumann, Lonza, Polypeptides, Sensirion and Swissquote. Strong investments continue to be made in the semiconductor industry and large investments are expected in the sector in Further Characteristics (3 years) / VAR (1 year) - share class CHF LC 2022 (Comet, VAT, Inficon). After the massive Volatility 14.31% Maximum Drawdown -15.20% VAR (99%/10 days) 6.77% price increases in the first few months, cyclical stocks moved little (ABB, Georg Sharpe Ratio -- Information Ratio -0.01 Correlation Coefficient 0.96 Fischer, Holcim). The shares of Cembra Alpha -1.55% Beta 1.12 Tracking Error 4.22% Money Bank were down significantly. The company surprisingly announced that Migros will end its collaboration in the credit card business in mid-2022. Investors are skeptical Portfolio Analysis about the future of Logitech, which has Breakdown by Sector (Equities) (in % of fund volume) Principal Holdings (Equities) (in % of fund volume) benefited greatly from its product portfolio Portfolio Breakdown according to MSCI (video and gaming) during the coronavirus Nestle SA (Consumer Staples) 9.6 period. Health Care 33.3 Roche Holding AG (Health Care) 9.5 Financials 15.7 Novartis AG (Health Care) 9.4 Industrials 14.6 Consumer Staples 13.7 Lonza Group AG (Health Care) 4.5 Materials 11.3 ABB Ltd (Industrials) 4.2 Consumer Discretionary 5.7 Zurich Insurance Group AG (Financials) 4.0 Information Technology 4.3 UBS Group AG (Financials) 3.6 Communication Services 1.2 Morningstar Style-Box™ Cie Financiere Richemont SA (Consumer Discretio 3.6 Market Capitalization Sika AG (Materials) 3.3 Large Alcon Inc (Health Care) 2.9 Total 54.6 Mid Gross weighting, not adjusted for derivative positions. Gross weighting, not adjusted for derivative positions. Small Breakdown by Currency (in % of fund volume) Asset Allocation (in % of fund volume) Swiss franc 99.9 Equities 99.8 Value Growth Euro 0.1 Cash and other assets 0.2 Blend Investment Style Morningstar Category™ Switzerland Equity Ratings (As at: 30/07/2021) Morningstar Overall Rating™: ««« Lipper Leaders: Incl. forward exchange transactions, negative and positive figures reflect expected currency developments. Note: The key terms are explained in the glossary. Page 1 / 7 Marketing Material DWS Aktien Schweiz Equity Funds - Europe - Regions/Countries August 2021 As at 31/08/2021 Portfolio Analysis Market Capitalization (in % of fund volume) > 10 Bn. 84.6 > 5 Bn. < 10 Bn. 9.6 > 1 Bn. < 5 Bn. 5.6 Gross weighting, not adjusted for derivative positions. The calculation is based on Euro. Key Figures regarding the Fund's Assets Number of Shares 40 Dividend Yield (in %) 2.1 Ø Market Cap 82,059.9 Mio. CHF Cumulative performance (in %) 1 m 1 y 3 y 5 y s. YTD 3 y avg 5 y avg 2017 2018 2019 2020 Inception CHF FC 3.4 33.2 51.0 5.2 5.2 24.6 14.7 1.0 21.7 -11.2 29.9 6.4 CHF LC 3.3 32.6 48.4 -0.1 -0.1 24.2 14.1 0.0 20.8 -11.8 29.0 5.8 EUR LD 3.0 31.9 -- -- 37.6 24.8 -- -- -- -- -- 6.3 Page 2 / 7 Marketing Material DWS Aktien Schweiz Equity Funds - Europe - Regions/Countries August 2021 As at 31/08/2021 Fund Data Portfolio Manager Ralf Rybarczyk Assets 391.0 Mio. CHF Portfolio Manager since 02/04/2007 Fund Currency CHF Portfolio Management Company DWS Investment GmbH Launch Date 02/04/2007 Portfolio Management Location Germany Fiscal Year End 30/09/2021 Management Company DWS Investment GmbH Investor profile Growth-oriented Legal Structure Fund Fund Domicile Germany Custodian State Street Bank International GmbH Share Classes Share Cur. ISIN Code Swiss Sec. Earnings Front-end Load Issue Price Redemption All-in-Fee Running costs / plus Minimum Class No. Price TER performance- Invest- related fee ment Amount CHF FC CHF DE000DWS1VC7 22145248 Accumulation 0.00% 105.24 105.24 0.800% 0.80% (1) -- 2,000,000 CHF LC CHF DE000DWS0D27 3029161 Accumulation 5.00% 104.89 99.89 1.300% 1.33% (1) -- -- EUR LD EUR DE000DWS23F6 51126505 Distribution 5.00% 143.46 136.62 1.300% 1.30% (2) -- -- (1) The Total Expense Ratio (TER) generally includes all expense items charged to the Fund apart from transaction costs and performance fees. If the Fund invests a substantial part of its assets in target funds, the costs of the respective funds and payments received by them will also be taken into account. The Fund incurred the total expenses listed here in its last financial year which ended on 30/09/2020. They are subject to change from year to year. (2) The Total Expense Ratio (TER) generally includes all expense items charged to the Fund apart from transaction costs and performance fees. The total expenses listed here represent an estimate since the Fund was launched on (EUR LD:05/12/2019). Actual expenses will be calculated and published once the first financial year has ended. The annual report for each financial year will contain the expense details with their precise calculation. Address Note DWS CH AG Because of its composition or the techniques used by its managers, the fund is subject to heightened volatility. Consequently, unit prices may fluctuate sharply in either direction within short periods of time. Hardstrasse 201 The rankings and ratings relating to German market. CH-8005 Zurich Prospective investors can obtain a copy of the current sales prospectus, including the terms of contract or management regulations, the articles of Tel.: +41 44 224 77 00 association, the prospectus and/or the key investor information the annual and semi-annual report free of charge from the representative in Switzerland, DWS CH AG, Hardstrasse 201, CH-8005 Zurich. Fax: +41 44 224 71 00 www.deutschefunds.ch E-Mail: [email protected] Page 3 / 7 Legal Disclaimer Opportunities In accordance with the investment policy. Risks • The fund invests its assets in selected regions or sectors. This increases the risk that the fund may be negatively influenced by the economic and political conditions in the respective regions or sectors.• The fund invests in equities. Equities are subject to strong price fluctuations and thus also to the risk of price decreases.• Due to its composition/the techniques used by the Fund management, the investment fund has elevated volatility, i.e. the share price may be subject to significant fluctuations up or down within short periods of time. The share value may fall below the purchase price at which the customer acquired the share at any time. Investor profile: Growth-oriented The Fund is intended for the growth-oriented investor seeking returns higher than those from capital market interest rates, with capital growth generated primarily through opportunities in the equity and currency markets. Security and liquidity are subordinate to potential high returns. This entails higher equity, interest rate and currency risks, as well as default risks, all of which can result in a loss of capital. Please note that the information from Morningstar and Lipper Leaders relates to the previous month. Morningstar Overall Rating™ © 2021 Morningstar, Inc. All rights reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete, or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results. Lipper Leaders © 2021 Lipper - Thomson Reuters Lipper. All rights reserved. Any copying, republication or redistribution of Lipper content is expressly prohibited without the prior written consent of Lipper. Neither Lipper, other members of the Thomson Reuters group, nor its data providers shall be liable for any errors or delays in the content or for any actions taken in reliance thereon. Lipper performance rankings are calculated using data available at the time of calculation and may not represent all the funds tracked by Lipper.
Load more

Recommended publications
  • Private Capital in Switzerland
    DOWNLOAD THE DATA PACK PRIVATE CAPITAL IN SWITZERLAND KEY FACTS 52 €632mn €1.9bn Total number of Average size of Average allocation to Switzerland-based Switzerland-based funds private capital among funds in market, closed in 2018 YTD across Switzerland-based targeting an aggregate all private capital. investors. €13bn. Fig. 2: Annual Switzerland-Based Private Capital Fig. 1: Annual Switzerland-Based Private Capital Fundraising by Asset Class, 2008 - 2018 YTD Fundraising, 2008 - 2018 YTD (As at October 2018) (As at October 2018) 39 100% 5 1.2 40 22 5.9 35 34 Natural Resources 35 32 33 30 31 80% 14.6 30 26 36 Private Debt 25 24 24 10.4 19 60% 20 16 Infrastructure 15 14.4 9.3 8.4 9.6 9.5 40% 10 7.8 6.9 6.2 6.8 Real Estate 5.8 212 55.2 5 2.5 Proportion of Total 0 20% Private Equity & 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 Venture Capital 0% YTD Year of Final Close No. of Funds Aggregate Capital No. of Funds Closed Aggregate Capital Raised (€bn) Closed Raised (€bn) Source: Preqin Pro Source: Preqin Pro Fig. 3: Switzerland-Based Private Capital: Median Net Fig. 4: Switzerland-Based Private Capital Assets under IRRs by Vintage Year (As at October 2018) Management by Asset Class, 2008 - 2018 18% 17.0%16.7% 50 16% 14.3% 40 14% 11.5% 11.3% 30 12% 10.9% 10.5% 10% 9.2% (€bn) 20 8.1% 8.5% 8% 6.4% 10 6% Assets under Management 4% 0 Median Net IRR since Inception 2% Dec-08 Dec-09 Dec-10 Dec-11 Dec-12 Dec-13 Dec-14 Dec-15 Dec-16 Dec-17 0% Mar-18 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 Private Equity Real Estate Infrastructure Vintage Year Private Debt Natural Resources Source: Preqin Pro Source: Preqin Pro 1 ©Preqin Ltd.
    [Show full text]
  • Update on Partners Group
    Update on Partners Group February 2021 Gonzalo Fernández Castro Private Equity Americas | Hal Avidano Co-Head Private Equity Integrated Investments Americas UPDATE ON PARTNERS GROUP 2 Table of contents 1 Overview 2 Clients 3 Industry 4 Investments 5 ESG 6 Financials OVERVIEW 3 About us Dedicated to private markets Leveraging strong resources • Our AuM stands at USD 109 billion:1 USD 52 billion in • We have over 1,500 employees worldwide2 across 20 corporate equity & USD 57 billion real assets / financing offices and over 750 private markets professionals • We leverage our database of over 36,000 private markets • Our platform, portfolio and network provide extensive assets to generate attractive deal flow synergies and opportunities for owners and entrepreneurs We have a global presence with 20 offices across key investment regions Tokyo Shanghai Seoul Toronto Dubai Denver London New York Mumbai Guernsey Luxembourg Manila Houston Munich Paris Singapore Zug Milan São Paulo Sydney Americas Europe Asia Pacific For illustrative purposes only. Source: Partners Group (2020). 1 Unaudited, inclusive of all Partners Group affiliates, as of 31 December 2020. 2 As of 31 December 2020. OVERVIEW 4 About our portfolio Partner to business Entrepreneurial ownership Corporate assets (USD 52 billion AuM1) Healthcare Industrials Consumer & services Technology Real assets / financing (USD 57 billion AuM2) Infrastructure Real estate Real asset services Financing We are "responsible for the dreams" of the 200,000+ partners and employees who work alongside us in our portfolio For illustrative purposes only. Source: Partners Group (2019). 1 Corporate equity includes Partners Group's private equity asset under management as of 31 December 2020.
    [Show full text]
  • 312.1.Full.Pdf
    Ann Rheum Dis: first published as 10.1136/annrheumdis-2021-eular.1066 on 19 May 2021. Downloaded from 312 Scientific Abstracts Acknowledgements: This study was funded by Novartis Pharma AG. The found many DEGs from baseline with GUS treatment and none with PBO. These authors thank Richard Karpowicz, PhD, of Health Interactions, Inc, for providing included genes related to B-, T-, NK-, and plasma cells (increased by GUS) and medical writing support/editorial support, which was funded by Novartis Pharma- neutrophils, monocytes, eosinophils, and macrophages (decreased by GUS), ceuticals Corporation, East Hanover, NJ, in accordance with Good Publication suggestive of a partial normalization of immune cell composition in whole blood. Practice (GPP3) guidelines (http://www.ismpp.org/gpp3). Conclusion: Using whole transcriptome profiling, we detected DEGs in blood Disclosure of Interests: Gurjit S. Kaeley Consultant of: Novartis Pharmaceuti- samples obtained from PsA pts vs. healthy controls, suggesting a dysregulation cals Corporation, Georg Schett Speakers bureau: AbbVie, Bristol Myers Squibb, of immune cell profiles in PsA. The majority of these disease-associated genes Celgene, Janssen, Eli Lilly, Novartis, and Pfizer, Consultant of: AbbVie, Bristol were modulated by GUS, with directionality toward a normalization of whole Myers Squibb, Celgene, Janssen, Eli Lilly, Novartis, and UCB, Grant/research blood transcriptomic signatures. support from: Bristol Myers Squibb, Celgene, GSK, Eli Lilly, and Novartis, Philip REFERENCES: G Conaghan Consultant of: or Speakers bureau: AbbVie, AstraZeneca, Bristol [1] Deodhar A et al. Lancet. 2020;395:1115. Myers Squibb, Eli Lilly, EMD Serono, Flexion Therapeutics, Galapagos, Gilead, [2] Mease P et al. Lancet. 2020;395:1126. Novartis, and Pfizer, Grant/research support from: UK National Institute for Health Research (NIHR) Leeds Biomedical Research Centre, Dennis McGona- Table 1.
    [Show full text]
  • SEB Fund 1 AR 31122019 Final Post BM
    Annual Report SEB Fund 1 Status: 31 December 2019 R.C.S K 49 Notice The sole legally binding basis for the purchase of units of the Fund described in this report is the latest valid Sales Prospectus with its terms of contract. Table of Contents Page Additional Information to the Investors in Germany 2 Organisation 3 General Information 5 Management Report 9 Schedule of Investments: SEB Fund 1 - SEB Asset Selection Fund 10 SEB Fund 1 - SEB Europe Index Fund 14 SEB Fund 1 - SEB Global Fund 24 SEB Fund 1 - SEB Global Chance / Risk Fund 33 SEB Fund 1 - SEB Norway Focus Fund 39 SEB Fund 1 - SEB Sustainability Fund Europe 41 SEB Fund 1 - SEB Sustainability Nordic Fund 46 SEB Fund 1 - SEB US All Cap 48 Combined Statement of Operations 50 Combined Statement of Changes in Net Assets 54 Combined Statement of Net Assets 58 Statistical Information 62 Notes to the Financial Statements 74 Audit Report 81 Risk Disclosure (unaudited) 84 Remuneration Disclosure (unaudited) 86 1 Additional Information to the Investors in Germany As at 31 December 2019 Units in circulation: The following Sub-Funds are publicly approved for distribution in Germany: • SEB Fund 1 - SEB Asset Selection Fund • SEB Fund 1 - SEB Global Fund • SEB Fund 1 - SEB Global Chance / Risk Fund • SEB Fund 1 - SEB Sustainability Fund Europe • SEB Fund 1 - SEB Sustainability Nordic Fund The following Sub-Funds are not distributed in Germany: • SEB Fund 1 - SEB Europe Index Fund • SEB Fund 1 - SEB Norway Focus Fund • SEB Fund 1 - SEB US All Cap The information disclosed above is as at 31 December 2019 and this may change after the year end.
    [Show full text]
  • Nextgen WEALTH MANAGERS 30.06.2020
    ESG Swiss Equities Certificate NextGen WEALTH MANAGERS 30.06.2020 Objective & Strategy ESG Swiss Equities certificate invests in a financial and ESG criteria scored weighted index. The index tracks Swiss financially sound companies that generate investment performance and integrate corporate social responsability, ethics and sustainability characteristics in order to have a long term positive environmental, social, governance (ESG) impact. It aims to be a reference by providing a specific solution that allows capital markets to redirect investment flows toward a more sustainable economy. Only companies with a financial and ESG score equal or above the median are eligible for inclusion in the ESG Swiss Equities Index. The dynamic strategy is based upon a synthetic notional investment allocation and reallocation in the Index Components following a specific and monitored process of eligibility defined by NextGen Wealth Managers SA. Monthly Comment Classification In June, the ESG Swiss Equities certificate registered a performance of 2.78% compared to Asset Type Equities May's 2.78%. The certificate’s benchmark, the Swiss Performance Index (SPI), performed Region Switzerland positively at 1.55% against 2.86% in the previous month. Since the beginning of the year, the Style ESG Systematic two baskets stand at -8.11% for the certificate and -3.13% for the benchmark. Since inception, cumulated performances are respectively at 12.34% and 34.73% (representing annualized performances of 2.72% and 7.12%) for annualized volatilities of 13.07% and 9.59%. The portfolio's allocation in large capitalization companies remains around 36% against 9% in middle capitalization companies and 54% in small capitalization companies.
    [Show full text]
  • Retirement Strategy Fund 2060 Description Plan 3S DCP & JRA
    Retirement Strategy Fund 2060 June 30, 2020 Note: Numbers may not always add up due to rounding. % Invested For Each Plan Description Plan 3s DCP & JRA ACTIVIA PROPERTIES INC REIT 0.0137% 0.0137% AEON REIT INVESTMENT CORP REIT 0.0195% 0.0195% ALEXANDER + BALDWIN INC REIT 0.0118% 0.0118% ALEXANDRIA REAL ESTATE EQUIT REIT USD.01 0.0585% 0.0585% ALLIANCEBERNSTEIN GOVT STIF SSC FUND 64BA AGIS 587 0.0329% 0.0329% ALLIED PROPERTIES REAL ESTAT REIT 0.0219% 0.0219% AMERICAN CAMPUS COMMUNITIES REIT USD.01 0.0277% 0.0277% AMERICAN HOMES 4 RENT A REIT USD.01 0.0396% 0.0396% AMERICOLD REALTY TRUST REIT USD.01 0.0427% 0.0427% ARMADA HOFFLER PROPERTIES IN REIT USD.01 0.0124% 0.0124% AROUNDTOWN SA COMMON STOCK EUR.01 0.0248% 0.0248% ASSURA PLC REIT GBP.1 0.0319% 0.0319% AUSTRALIAN DOLLAR 0.0061% 0.0061% AZRIELI GROUP LTD COMMON STOCK ILS.1 0.0101% 0.0101% BLUEROCK RESIDENTIAL GROWTH REIT USD.01 0.0102% 0.0102% BOSTON PROPERTIES INC REIT USD.01 0.0580% 0.0580% BRAZILIAN REAL 0.0000% 0.0000% BRIXMOR PROPERTY GROUP INC REIT USD.01 0.0418% 0.0418% CA IMMOBILIEN ANLAGEN AG COMMON STOCK 0.0191% 0.0191% CAMDEN PROPERTY TRUST REIT USD.01 0.0394% 0.0394% CANADIAN DOLLAR 0.0005% 0.0005% CAPITALAND COMMERCIAL TRUST REIT 0.0228% 0.0228% CIFI HOLDINGS GROUP CO LTD COMMON STOCK HKD.1 0.0105% 0.0105% CITY DEVELOPMENTS LTD COMMON STOCK 0.0129% 0.0129% CK ASSET HOLDINGS LTD COMMON STOCK HKD1.0 0.0378% 0.0378% COMFORIA RESIDENTIAL REIT IN REIT 0.0328% 0.0328% COUSINS PROPERTIES INC REIT USD1.0 0.0403% 0.0403% CUBESMART REIT USD.01 0.0359% 0.0359% DAIWA OFFICE INVESTMENT
    [Show full text]
  • Partners Group Global Value Sicav
    PARTNERS GROUP GLOBAL VALUE SICAV Monthly report as of 31 October 2019 NAV eased by 0.4% in October This Fund might restrict outflows in the future. IMPORTANT INFORMATION: We would like to remind investors that redeeming ● New private equity direct transaction Nestlé Skin Health their holdings in the Fund is subject to restrictions as set out in the Fund's constitu- ent documents. Redemptions are generally subject to a maximum per dealing day ● Private equity direct investment Guardian Childcare & Education closed expressed as a percentage of the net asset value. These percentages may be lowered further (limited to a maximum of 2 consecutive years) if this is deemed an add-on acquisition in the best interest of the Fund. In certain circumstances redemptions may also be suspended. In October, Partners Group Global Value SICAV I EUR recorded, with a NAV development of -0.4%, the first negative month in 2019 and closed at a Key figures share price of EUR 259.40. The lower share price was the result of an unfa- In EUR 30.09.2019 31.10.2019 YTD vorable development of the FX movements that more than offset the slightly positive performance of the portfolio. Notwithstanding this, the Fund con- NAV per share 260.53 259.40 9.7% tinued to build out the underlying portfolio by completing the investment Total fund size (in million) 3'429.09 3'568.06 in Nestlé Skin Health and the funding of an add-on acquisition by Guardian Investment level 96.4% 93.8% Childcare & Education. Performance (since inception) 160.5% 159.4% Monthly volatility (since inception) 4.5% 4.5% The largest transaction of the reporting month was Partners Group's invest- ment in Nestlé Skin Health.
    [Show full text]
  • Annual Report 2014
    ANNUAL REPORT 2014 Dress €99 Blazer €19.99 H&M SPRING 2015 MODERN ESSENTIALS SELECTED BY DAVID BECKHAM SPRING 2015 Shirt €19.99 H&M SPRING 2014 Sweater € 19.95 — H&M ANNUAL REPORT 2014 — Contents H&M IN WORDS AND PICTURES This is H&M 8 CEO letter 10 2014 in brief 12 Our brands 16 Sustainable development 36 Our employees 42 Expansion 46 History 54 H&M IN FIGURES Administration report, including proposed distribution of earnings 60 Group income statement 66 Consolidated statement of comprehensive income 66 Group balance sheet 67 Group changes in equity 68 Group cash flow statement 69 Parent company income statement 70 Parent company statement of comprehensive income 70 Parent company balance sheet 71 Parent company changes in equity 72 Parent company cash flow statement 73 Notes to the financial statements 74 Signing of the annual report 90 Auditor’s report 91 Corporate governance report, including information about the board of directors 92 Auditor’s statement on the corporate governance report 104 Five year summary 106 The H&M share 107 Financial information and contact details 108 H&M’s annual accounts and consolidated accounts for the financial year 2013/14 comprise pages 60–90. — THIS IS H&M — Fashion and quality at the best price H&M is a leading global fashion company with strong values and a clear business concept. H&M has a passion for fashion, a belief in people and a desire to always exceed customers’ expectations – and to do so in a sustainable way. H&M’s busi- ness concept is to offer fashion and quality at the best price.
    [Show full text]
  • Sika Annual Report 2011 1 → Content
    Online Annual Report 2011 → www.annualreport.sika.com 2011 � Sika Annual Report For Jean Nouvel, a 32000 m² façade clad with 6500 perfectly jointed glass panels. � For Daniel Libeskind, a 1400 m² roof that Freedom of Design Acceleration The precision-designed Sikasil® silicone joints are essential to Sika superplasticizers and shrinkage-reducing admixtures were the glass façade's filigree aesthetic, rigorous color scheme and instrumental in delivering a handsome fair-faced concrete finish environmental control performance. and to keep the tight construction schedule. reads as a fifth façade, sloping at 37° from 90 to 180 meters in height. Turning architects’ visions into reality, drawing on in-depth experience and know-how to translate ideas into buildings and works of art – that is one side to Sika's definition of customer focus. The other is to offer variety, deliver quality and build trust. In all aspects of technology, materials and practical application. Its mission is to create fresh scope for ideas, formal designs and connecting assemblies which, in many cases, are still waiting to be discovered. Sika Annual Report 2011 1 → Content Content Robust Growth Customer Focus 3 Letter to Shareholders 66 Freedom of Design 72 i-Cure Technology Investing in Sika 75 Acceleration 7 Stock price development 9 Risk Management Financial Report 80 Consolidated Financial Statements Strategy & Focus 85 Appendix to the Consolidated 13 Group Strategy Financial Statements 14 The Sika Brand 133 Five-Year Reviews 15 Customers & Markets 140 Sika AG Financial
    [Show full text]
  • Offense Remains the Best Defense
    Offense remains the best defense Private Markets Navigator Outlook 2021 Tina Jessop Senior Economist | Charles Rees Private Equity Europe Table of contents Private markets outlook 04 Private equity 10 The industry view 18 Private real estate 21 Private debt 27 Private infrastructure 32 Liquid private markets 37 Portfolio perspectives 38 Contacts 46 Important information This material has been prepared solely for purposes of illustration and Partners Group expressly disclaims any obligation or undertaking to discussion. Under no circumstances should the information contained update or revise any projections, forecasts, or estimates contained in herein be used or considered as an offer to sell or solicitation of an offer this material to reflect any change in events, conditions, assumptions, to buy any security. The information contained herein is proprietary and or circumstances on which any such statements are based unless so may not be reproduced or circulated in whole or in part. required by applicable law. All information, including performance information, has been prepared Private markets investments are speculative and involve a substantial in good faith; however, Partners Group makes no representation or degree of risk. Private markets investments are highly illiquid and are warranty, express or implied, as to the accuracy or completeness of not required to provide periodic pricing or valuation information to the information, and nothing herein shall be relied upon as a promise investors with respect to individual investments. There is no secondary or representation as to past or future performance. This material may market for the investors’ interest, and none is expected to develop. In include information that is based, in part or in full, on hypothetical addition, there may be certain restrictions on transferring interests.
    [Show full text]
  • Fund Holdings
    Wilmington International Fund as of 7/31/2021 (Portfolio composition is subject to change) ISSUER NAME % OF ASSETS ISHARES MSCI CANADA ETF 3.48% TAIWAN SEMICONDUCTOR MANUFACTURING CO LTD 2.61% DREYFUS GOVT CASH MGMT-I 1.83% SAMSUNG ELECTRONICS CO LTD 1.79% SPDR S&P GLOBAL NATURAL RESOURCES ETF 1.67% MSCI INDIA FUTURE SEP21 1.58% TENCENT HOLDINGS LTD 1.39% ASML HOLDING NV 1.29% DSV PANALPINA A/S 0.99% HDFC BANK LTD 0.86% AIA GROUP LTD 0.86% ALIBABA GROUP HOLDING LTD 0.82% TECHTRONIC INDUSTRIES CO LTD 0.79% JAMES HARDIE INDUSTRIES PLC 0.78% DREYFUS GOVT CASH MGMT-I 0.75% INFINEON TECHNOLOGIES AG 0.74% SIKA AG 0.72% NOVO NORDISK A/S 0.71% BHP GROUP LTD 0.69% PARTNERS GROUP HOLDING AG 0.65% NAVER CORP 0.61% HUTCHMED CHINA LTD 0.59% LVMH MOET HENNESSY LOUIS VUITTON SE 0.59% TOYOTA MOTOR CORP 0.59% HEXAGON AB 0.57% SAP SE 0.57% SK MATERIALS CO LTD 0.55% MEDIATEK INC 0.55% ADIDAS AG 0.54% ZALANDO SE 0.54% RIO TINTO LTD 0.52% MERIDA INDUSTRY CO LTD 0.52% HITACHI LTD 0.51% CSL LTD 0.51% SONY GROUP CORP 0.50% ATLAS COPCO AB 0.49% DASSAULT SYSTEMES SE 0.49% OVERSEA-CHINESE BANKING CORP LTD 0.49% KINGSPAN GROUP PLC 0.48% L'OREAL SA 0.48% ASSA ABLOY AB 0.46% JD.COM INC 0.46% RESMED INC 0.44% COLOPLAST A/S 0.44% CRODA INTERNATIONAL PLC 0.41% AUSTRALIA & NEW ZEALAND BANKING GROUP LTD 0.41% STRAUMANN HOLDING AG 0.41% AMBU A/S 0.40% LG CHEM LTD 0.40% LVMH MOET HENNESSY LOUIS VUITTON SE 0.39% SOFTBANK GROUP CORP 0.39% NOVARTIS AG 0.38% HONDA MOTOR CO LTD 0.37% TOMRA SYSTEMS ASA 0.37% IMCD NV 0.37% HONG KONG EXCHANGES & CLEARING LTD 0.36% AGC INC 0.36% ADYEN
    [Show full text]
  • Julius Baer Multistock
    JULIUS BAER MULTISTOCK A SICAV UNDER LUXEMBOURG LAW PROSPECTUS 31 DECEMBER 2011 Subscriptions are validly made only on the basis of this Prospectus or the Key Investor Information Document in conjunction with the most recent annual report and the most recent semi-annual report where this is published after the annual report. No information other than that contained in this Prospectus or the Key Investor Information Document may be given. PROSPECTUS - 2 - JULIUS BAER MULTISTOCK TABLE OF CONTENTS 1. Introduction..................................................................................................................................................5 2. Organisation and management...................................................................................................................8 3. Investment objectives and policy..................................................................................................................10 4. Investor profile...........................................................................................................................................34 5. Investment limits........................................................................................................................................35 6. Special investment techniques and financial instruments ........................................................................41 6.1 Options on securities....................................................................................................................................
    [Show full text]